Startseite Kongressberichte & Archiv 2021 ASCO Annual Meeting Lung Cancer Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC).
Heather A. Wakelee, Nasser K. Altorki, Caicun Zhou, et al.
According to the authors of the study IMpower010 met its primary endpoint, showing a benefit in disease-free survival with adjuvant atezolizumab vs best supportive care after adjuvant chemo in patients with resected Stage II-IIIA NSCLC, with pronounced benefit in the PD-L1 TC ≥1% subgroup. There were no new safety signals with atezolizumab monotherapy across indications and lines of therapy. Clinical trial information: NCT02486718
Adjuvant gefitinib versus cisplatin/vinorelbine in Japanese patients with completely resected, EGFR-mutated, stage II-III non-small cell lung cancer (IMPACT, WJOG6410L): A randomized phase 3 trial.
Hirohito Tada, Tetsuya Mitsudomi, Takeharu Yamanaka, et al.
According to the authors of the study, adjuvant gefitinib prevented early relapse but did not significantly prolong disease-free or overall survival in patients with completely resected stage II-III, EGFR-mutated NSCLC. The authors conclude, that the apparent non-inferiority may justify adjuvant gefitinib in a selected subset of patients, especially those deemed unsuitable for adjuvant cisplatin/vinorelbine therapy. Clinical trial information: UMIN000006252.
CTONG1103: Final overall survival analysis of the randomized phase 2 trial of erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non–small cell lung cancer.
Yi-Long Wu, Wenzhao Zhong, Ke-Neng Chen, et al.
According to the authors of the study, neoadjuvant/adjuvant Erlotinib therapy for resected N2 NSCLC was feasible and had a promising overall survival. The progression-free survival advantage of Erlotinib did not translate to an overall survival difference in the EMERGING trial. Clinical trial information: NCT01407822
Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC).
Jonathan Spicer, Changli Wang, Fumihiro Tanaka, et al.
According to the authors of the study, CheckMate 816 (NCT02998528) is a randomized phase 3 study of neoadjuvant nivolumab + chemotherapy, which did not impede the feasibility and timing of surgery, nor the extent or completeness of resection vs chemo alone; the authors state, that therapy was tolerable and did not increase surgical complications. An increased depth of pathological response was observed. The authors conclude, that CheckMate 816's surgical outcome results along with significant improvement in pathological complete response support nivolumab + chemotherapy as a potential neoadjuvant option for patients with stage IB to IIIA resectable NSCLC. Clinical trial information: NCT02998528
Video-assisted thoracoscopic versus open lobectomy in patients with early-stage lung cancer: One-year results from a randomized controlled trial (VIOLET).
Eric Kian Saik Lim, Tim J.P. Batchelor, Joel Dunning, et al.
According to the authors of the study, Video-assisted thoracoscopic surgery (VATS) lobectomy for lung cancer is associated with less pain, fewer in-hospital complications, and shorter hospital stays. It was achieved without any compromise to early oncologic outcomes nor serious adverse events. It was observed, that the superior functional recovery continues in the post-operative period with improved physical function, lower re-admission rates, and no difference in disease-free and overall survival up to one year. Clinical trial information: ISRCTN13472721.
Phase 3 comparison of high-dose once-daily (QD) thoracic radiotherapy (TRT) with standard twice-daily (BID) TRT in limited stage small cell lung cancer (LSCLC): CALGB 30610 (Alliance)/RTOG 0538.
Jeffrey A Bogart, Xiaofei F. Wang, Gregory A. Masters, et al.
According to the authors of the study, high dose once-daily thoracic radiotherapy (TRT) to 70 Gy did not significantly improve overall survival compared with standard 45 Gy standard twice-daily TRT. But favorable outcomes on the high-dose once-daily arm show the most robust evidence available supporting high dose once-daily thoracic radiotherapy as an acceptable option in LSCLC. The authors conclude, that outcomes from this largest study conducted in LSCLC will help guide thoracic radiotherapy decisions for this patient population. Clinical trial information: NCT00632853
Stereotactic ablative radiotherapy in operable stage I NSCLC patients: Long-term results of the expanded STARS clinical trial.
Joe Y. Chang, Reza J. Mehran, Lei Feng, Peter Balter, et al.
According to the authors of the study, the long-term overall and disease-free survival of stereotactic ablative radiotherapy (SABR) is not inferior to video-assisted thoracoscopic mediastinal lymph node dissection for operable stage IA NSCLC. They conclude, that SABR remains a promising approach for this population, but they strongly recommend multidisciplinary management. Clinical trial information: NCT02357992
A randomized phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma.
Dean Anthony Fennell, Angela Claire Casbard, et al.
According to the authors of the study, the trial met its primary endpoint with vinorelbine demonstrating useful clinical efficacy in relapsed MPM. This supports an off-label treatment option for patients with relapsed MPM. Busacca et al, J Pathol 2012, 227(2), 200.  Busacca et al, Mol Cancer Res, 2021, 20(2) 379. Clinical trial information: NCT02139904